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Abstract: 
Investigation of kinase-related processes often uses pharmacological 
inhibition to reveal pathways in which kinases are involved. However, one 
concern about using such kinase inhibitors is their potential lack of specificity. 
Here, we report that the calcium-calmodulin dependent kinase II (CaMKII) 
inhibitor CK59 inhibited multiple voltage-gated calcium channels, including 
the L-type channel during depolarization in a dose-dependent manner. The 
use of another CaMKII inhibitor, cell permeable autocamtide 2-related 
inhibitory peptide II (Ant-AIP-II), failed to similarly decrease calcium current 
or entry in hippocampal cultures, as shown by ratiometric calcium imaging 
and whole cell patch clamp electrophysiology. Notably, inhibition due to CK59 
was reversible; washout of the drug brought calcium levels back to control 
values upon depolarization. Furthermore, the IC50 for CK59 was 
approximately 50 μM, which is only five fold larger than the reported IC50 
values for CaMKII inhibition. Similar nonspecific actions of other CaMKII 
inhibitors KN92 and KN62 have previously been reported. In the case of all 
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three kinase inhibitors, the IC50 for calcium current inhibition falls near that of 
CaMKII inhibition. Our findings demonstrate that CK59 attenuates activity of 
voltage-gated calcium channels, and thus provide more evidence for caution 
when relying on pharmacological inhibition to examine kinase-dependent 
phenomena. 
Keywords: Calcium-calmodulin dependent kinase II, CaMKII, calcium 
channel, kinase inhibitor, nonspecific inhibition. 
 
Introduction 
`Calcium-calmodulin dependent kinase II (CaMKII) is a crucial 
signaling molecule involved in many of the most fundamental 
behaviors of neurons, such as gene expression and synaptic plasticity 
due to long term potentiation. It follows that the distribution of this 
protein is widespread throughout the nervous system, and makes up 
between 1 – 2% of total protein content in neurons. Given both its 
importance and its abundance, CaMKII mediated processes are 
currently under intense investigation. One of the most common ways 
to study the activity of CaMKII is to inhibit it with pharmacological 
agents, then investigate changes in the neuron when CaMKII is no 
longer active. Unfortunately, a common problem with kinase inhibitors, 
including CaMKII inhibitors, is their lack of specificity. Therefore, new, 
more specific inhibitors are always in demand. This demand extends to 
a clinical setting, where more specific CaMKII inhibitors may help avoid 
potentially harmful side effects. 
Over 30 different isoforms (made up of various alternatively 
spliced α, β, δ, and γ subunits) of CaMKII have been reported (for 
review, see Fink and Meyer, 2002; Wayman et al., 2011). The primary 
neuronal subunits are α and β, which are highly homologous. Subunits 
come together either as homo- or heterododecihedromers, with each 
subunit containing a catalytic, regulatory, and oligomerization domain. 
The structure of CaMKII is often described as a petal, where the 
oligomerization domain makes up the inner core, while the catalytic 
and regulatory domains form a stack of 2 hexomers (Gaertner et al., 
2004; Rosenberg et al., 2006). When calmodulin (CaM) binds to the 
regulatory domain, autoinhibition is disrupted, and the particular 
subunit interacting with CaM is free to autophosphorylate neighboring 
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subunits, which causes their catalytic subunits to become active. 
Kinase inhibitors reduce the activity of the enzyme in different ways. 
For example, one of the most commonly used inhibitors, KN93 works 
to compete with CaM binding to the regulatory domain. This is in 
contrast to an inhibitor such as autocamtide 2-related inhibitory 
peptide (AIP); unlike KN agents, AIP also inhibits the catalytic function 
of activated CaMKII (Ishida et al., 1995; Song et al., 2010). Thus, with 
many different forms of inhibition may come many different off target 
effects. 
CaMKII phosphorylates a wide variety of proteins to modulate 
their activity, including voltage gated calcium channels. Calcium 
channels are implicated in a diverse array of physiological processes, 
such as muscle contraction, neurotransmitter release, and gene 
expression. In neurons, there are 3 classes of voltage gated calcium 
channels, based on their pore-forming α1 subunit (Cav 1.x, Cav 2.x, 
and Cav 3.x, for review see Catterall, 2011). They can further be 
divided into various isoforms based on their pharmacological and 
kinetic profiles. For example, Cav 1.2 and Cav 1.3 are sensitive to 
dihydropyridines, activate at high voltages, and are known as L-type 
channels for their long lasting current. Cav 2.1 and Cav 2.2 are known 
as N- and P/Q-type channels, are sensitive to certain cone snail toxins, 
and mediate synaptic release. Cav 2.3 was given the name R-type 
channel due to its resistance to most channel toxins, with a partial 
exception being the scorpion toxin SNX-482. Calcium channels are 
extensively regulated, either positively or negatively. Regulation 
occurs at various sites on the N- and C-terminals, or within the 
intracellular loops of the channel. G protein βγ subunits (Li et al., 
2004) as well as multiple protein kinases (Mitterdorfer et al., 1996; 
Park et al., 2006; Wang et al., 2009, Bray and Mynlieff, 2011) have 
been shown to interact with all types of voltage gated calcium 
channels. Since levels of intracellular calcium often work as a switch 
for many physiological processes, there is a great deal of interest 
surrounding how the behavior of these channels can be modified by 
various signaling molecules. 
Kinase inhibitor studies have been complicated by nonspecificity 
and off target effects of compounds used to inhibit CaMKII. An 
example of this nonspecificity is the interaction of the CaMKII inhibitor 
KN93 with calcium channels (Gao et al., 2006). Previously regarded as 
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one of the cleanest, most potent CaMKII inhibitors in existence, KN93 
was shown to reversibly inhibit only L-type calcium channels. Thus, 
studies investigating processes or pathways involving both CaMKII and 
L-type channels will be confounding without the use of other, more 
specific inhibitors. Recently Konstantopoulos et al. have developed a 
compound known as CK59 which has been shown to inhibit CaMKII 
activity (Konstantopoulos et al., 2007). While originally created to 
investigate the kinase responsible for insulin mediated GLUT 4 glucose 
transporter translocation, CK59 also offered an attractive option to 
those studying CaMKII and calcium channels, due to its potency (IC50 
<10 μM) and cell permeability. However, data here suggest that 
similarly to KN93, CK59 also inhibits calcium channels in a reversible 
manner, despite being structurally distinct. Furthermore, while L-type 
channels appear to be dramatically inhibited, it appears to inhibit other 
voltage-gated calcium channels as well. 
Methods 
Hippocampal cell culture 
All animal protocols were approved by the Marquette University 
Institutional Animal Care and Use Committee and followed the 
guidelines set forth by the U.S. Public Health Service. Briefly, neurons 
from the superior region of the neonatal rat hippocampus were 
cultured as previously described (Mynlieff, 1997). Neurons were 
dissociated from 6–8 day old Sprague-Dawley rat pups, plated on 
poly-L-lysine coated dishes (1 mg/mL, MW 38,500–60,000; Sigma-
Aldrich, St. Louis MO) and kept in culture for 20–24 hours to allow 
recovery from enzymatic digestion before experimentation. Cultures 
were maintained in Neurobasal A media supplemented with B27 (Life 
Technologies, Carlsbad CA), 0.02 mg/mL gentamicin (Life 
Technologies), and 0.5 mM L-glutamine (Sigma-Aldrich). 
Calcium Imaging 
Cultured neurons were incubated in 5 μM Fura-2 acetoxymethyl 
ester (Fura-2 AM, Life Technologies, Carlsbad CA) in calcium imaging 
Ringer’s solution (CIR, 154 mM NaCl, 5.6 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, 10 mM HEPES, 11 mM glucose, pH 7.4 with NaOH) for 1 hour at 
room temperature in the dark. Cells were rinsed and incubated for 30 
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minutes at room temperature in CIR without Fura-2 AM to allow for 
de-esterification. Depolarization was induced by application of high 
potassium solution (100 mM NaCl, 50 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, 10 mM HEPES, 11 mM glucose, pH to 7.4 with NaOH) for 30 
secoonds to open voltage-gated calcium channels. Inhibitors were 
perfused onto the cells in CIR for 15 seconds, followed by high KCl 
solution with inhibitor for 35 seconds. Neurons were excited at 340 nm 
and 380 nm, and emissions were measured at 510 nm using Slidebook 
5.0 software (Intelligent Imaging Innovations, Denver CO). The ratio 
of the emissions intensity when Fura-2 is excited at 340 nm and 380 
nm is directly correlated to changes in intracellular calcium 
(Grynkiewicz et al., 1985). Average data represent the mean ± SEM. 
Electrophysiology 
Whole cell electrophysiological recordings were performed as 
described previously (Carter and Mynlieff, 2004; Bray and Mynlieff, 
2009; Bray and Mynlieff, 2011). Data were acquired using a Dagan 
3900A patch clamp amplifier (Dagan Corporation, Minneapolis MN), 
Digidata 1322A acquisition setup, and pClamp 10.0 software 
(Molecular Devices, Sunnyvale CA). The extracellular solution 
contained 10 mM CaCl2, 145 mM tetraethylammonium chloride, 10 mM 
HEPES, and 1 μM tetrodotoxin (Sigma-Aldrich, St. Louis MO), pH 7.4. 
Recording electrodes with resistances of 3–8 MΩ were pulled from 
borosilicate glass on a Flaming/Brown Micropipette Puller (model P87, 
Sutter Instrument Co., Novato CA) and filled with 140 mM Cs-
aspartate, 5 mM MgCl2, 10 mM Cs2EGTA, 10 mM HEPES, 2 mM ATP-
Na2, and 0.1 mM GTP, pH 7.4. Cells were held at −80 mV and 
depolarized with a 300 ms pulse to +10 mV. Whole cell currents were 
electronically filtered at 1 kHz and digitized at 2 kHz. Linear 
components of leak current were subtracted posthoc by the passive 
resistance protocol in pClamp 10.0. CaMKII inhibitors were applied to 
the cells using a U-tube delivery system, constructed with PE-10 
polyethylene tubing housed in a glass tube, which allowed for rapid 
application and removal of the compound that was gravity fed onto the 
cell and removed via suction. Averaged data represent the mean ± 
SEM. 
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Chemicals and reagents 
The cell permeable CaMKII inhibitor 2-(2-Hydroxyethylamino)-
6-aminohexylcarbamic acid tert-butyl ester-9-isopropylpurine (CK59, 
EMD Millipore, IC50 < 10 μM) was dissolved in DMSO and diluted 
1:200,000-1:250 to produce final concentrations between 500 nM and 
250 μM. A second CaMKII inhibitor, cell permeable autocamtide-2 
related inhibitory peptide II (Ant-AIP-II, EMD Millipore catalog 
#189485), was dissolved in distilled water and diluted 1:1000 to 
produce a final concentration of 50 nM. This compound is an 
autocamtide-2 related inhibitory peptide (AIP) analog that contains the 
Antennapedia transport peptide sequence fused to the amino terminus 
of autocamtide-2 related inhibitory peptide II (AIP-II, EMD Millipore 
catalog #189484, IC50 = 4 nM) to enhance cell permeability. Ant-AIP-
II has been demonstrated to successfully enter both glia and neurons 
in culture (Watterson et al., 2001; Mauceri et al., 2004). In 
electrophysiological experiments designed to block N and P/Q channel 
activity, 2 μM ω-conotoxin MVIIC (Sigma-Aldrich, St. Louis MO) was 
added to the bath and U-tube. In experiments where L-channel activity 
was blocked, 20 μM nimodipine (Tocris Bioscience, Minneapolis MN) 
was added to the bath and U-tube in electrophysiological experiments, 
or perfused onto the cells in calcium imaging experiments. 
Results 
CK59 inhibits depolarization induced calcium entry 
The effects of CaMKII inhibitors CK59 and Ant-AIP-II were first 
explored with the use of ratiometric calcium imaging. Cells were 
depolarized with a high KCl solution in the presence and absence of 
various CaMKII inhibitors. Cells were treated with CK59 for 15 seconds 
prior to the depolarization with high KCl. There was no change in the 
fluorescence ratio during this pretreatment suggesting that CK59 does 
not affect the baseline extrusion levels of calcium. It is clear that in the 
presence of CK59 (50 μM) the high KCl solution was not able to elicit 
as large an increase in intracellular calcium (Fig. 1A). This effect was 
reversible, as the response to a KCl-induced depolarization after 
washout of CK59 was restored to the pre-CK59 level. In contrast, the 
increase in intracellular calcium with the high KCl solution was not 
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affected by the inclusion of the second CaMKII inhibitor, Ant-AIP-II (50 
nM, Fig. 1B). On average, the increase in intracellular calcium with 
high KCl stimulation was reduced to 44.83 ± 1.88% of control with 
CK59 (N = 128; paired t-test, p<0.001) and only reduced to 94.68 ± 
1.29% of control with Ant-AIP-II (N = 255, Fig. 1C). This result 
together with the lack of effect on baseline extrusion suggests that the 
novel CaMKII inhibitor CK59 shows off target inhibition of voltage 
gated calcium channels. However, the data do not exclude the 
possibility that there may be effects on extrusion in the presence of 
high intracellular calcium. 
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Fig. 1 CaMKII inhibitor CK59 but not Ant-AIP-II significantly attenuates the amount 
of high KCl induced increase in intracellular calcium when measured with Fura-2 
ratiometric imaging. A) Example of 340/380 ratio obtained with high KCl solution alone 
or high KCl solution in the presence of 50 μM CK59. Each line shown represents an 
individual cell (N=6). B) The same conditions as in A, but using 50 nM Ant-AIP-II 
(N=6). C) Average change in intracellular calcium as determined by the 340/380 ratios 
with KCl alone (solid bars), KCl with CK59 (crossed hash bar, N = 128), or KCl with 
Ant-AIP-II (diagonal hashed bar, N = 255). *Paired t-test, p < 0.001). 
High KCl-induced increases in intracellular calcium were 
measured in the presence of 500 nM – 250 μM CK59 (Fig. 2). The 
solubility of CK59 in DMSO limited the highest concentration used to 
250 μM. Control experiments with DMSO, diluted 1:250 in CIR with no 
CK59, verified that DMSO alone did not affect high KCl-induced 
calcium influx at this concentration (data not shown). The dose-
response curve data was fit with a 3 parameter sigmoidal curve that 
assumed if the concentration was increased to high enough levels, all 
calcium entry would be blocked. The curve generated an IC50 of 52 μM. 
It is possible this is an overestimate; if all calcium entry is not 
completely inhibited and instead 70% CK59 mediated inhibition is the 
actual maximum, then the IC50 would be closer to 22 μM. CK59’s IC50 
for inhibition of CaMKII activity is < 10 μM. Other nonspecific CaMKII 
inhibitors that inhibit L-type calcium channels are more potent, both in 
their primary and off target effects. For example, the IC50 for KN93’s 
effect on CaMKII is 0.37 μM (Sumi et al., 1991), whereas its IC50 for L-
type channel inhibition is approximately 1 μM (Gao et al., 2006). The 
IC50 of a related inhibitor, KN62, is 0.9 μM for CaMKII activity; the IC50 
for its off target effects on calcium entry is approximately 0.5 μM 
(Sihra and Pearson, 1995). Given the relatively close IC50 values for 
primary and off target effects of these CaMKII inhibitors, one must be 
extremely cautious when selecting a compound to inhibit CaMKII 
activity. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Cellular and Molecular Neurobiology, Vol. 33, No. 5 (July 2013): pg. 723-729. DOI. This article is © Springer and 
permission has been granted for this version to appear in e-Publications@Marquette. Springer does not grant permission 
for this article to be further copied/distributed or hosted elsewhere without the express permission from Springer. 
9 
 
 
Fig. 2 Various doses (0.5, 5, 20, 50, and 250 μM; n = 122, 51, 166, 326, and 122, 
respectively) of CK59 were applied to cells during high KCl-induced depolarization. The 
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percent inhibition of high KCl induced intracellular calcium by CK59 was calculated as 
100%−(100×(Fura Ratio in CK59+KCl)/(Fura Ratio in KCl)). Data were fit with a 3 
parameter sigmoidal curve (r2 = 0.983). This allowed calculation of the IC50 value for 
CK59, 52 μM. 
The effects of CK59 on voltage gated calcium currents was 
measured directly using whole cell patch clamp recording. Figure 3 
illustrates the calcium current elicited in the presence and absence of 
CK59 (50 μM). The total current was reduced with CK59 in a reversible 
manner (Fig. 3A). Calcium currents often change during recording so 
that the data were adjusted for run-up or run-down prior to measuring 
the magnitude of current inhibited (Carter and Mynlieff, 2004; Bray 
and Mynlieff, 2009; Bray and Mynlieff, 2011). Typically a few control 
currents were measured both before and after CK59 application. These 
currents were fit with a linear regression and the current in the 
presence of CK59 was compared back to the linear regression line 
(“expected current in the absence of inhibitor”; Fig. 3B). A change in 
the current magnitude was only considered significant if it fell outside 
of the 95% confidence interval for the linear regression (dashed line in 
Fig. 3B). In all 15 cells tested, CK59 significantly reduced the current 
with an average reduction of 32.05 ± 1.86% when compared to the 
linear regression line (Fig. 3E). The difference in reduction of calcium 
entry observed when using ratiometric calcium imaging versus whole 
cell patch clamp electrophysiology likely stems from the length of time 
neurons are stimulated. In calcium imaging experiments, neurons 
were depolarized for 30 seconds so that the majority of calcium influx 
is through long lasting L-type channels, whereas electrophysiological 
experiments depolarize neurons for a relatively short 300 ms. The 
currents measured in response to a short depolarization to +10 mV 
are likely comprised of L-, N-, P/Q-, and R-type currents. As seen with 
ratiometric calcium imaging, electrophysiological recordings illustrate 
the nonspecificity of CaMKII inhibitor CK59, as it decreases voltage 
gated calcium current. 
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Fig. 3 Calcium currents elicited by a 300 ms depolarizing pulse to +10 mV from a 
holding potential of −80 mV demonstrates the nonspecific effects of CK59 on calcium 
channel types. A) CK59 application reduces current in normal recording solution. 
Voltage gated calcium currents were recorded before (black trace), during (gray trace) 
and after (light gray trace) application of CK59. B) Control calcium currents were 
measured before and after CK59 application (filled circles) and fit with a linear 
regression line and 95% confidence interval (dashed line). Calcium currents elicited in 
the presence of CK59 (gray diamonds) fell outside of the confidence interval for the 
control currents. The percent of current blocked by CK59 was calculated by comparing 
the current in the presence of CK59 to the regression line for that specific time point. 
C) 20 μM nimodipine was bath applied and voltage gated calcium currents were 
recorded before (black trace), during (gray trace) and after (light gray trace) 
application of CK59 (50 μM). D) 2 μM ω-conotoxin MVIIC was bath applied and voltage 
gated calcium currents were recorded before (black trace), during (gray trace) and 
after (light gray trace) application of CK59 (50 μM). The traces illustrated in A, C, and 
D were recorded in different neurons. E) Average decrease in voltage gated calcium 
current seen with CK59 application (50 μM) in control bathing solution (N=15), with 
20 μM nimodipine (N=7), and with 2 μM ω-conotoxin MVIIC (N=5) in the bath. 
*Unpaired t-test, p < 0.001. 
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CK59 decreases calcium entry through more than one 
voltage gated calcium channel 
Since it had previously been reported that the CaMKII inhibitor 
KN93 reduced L-type calcium current, we sought to assess whether L-
type calcium channels were similarly inhibited by CK59 with whole cell 
recording. Calcium currents were measured during the final 50 ms of a 
300 ms depolarizing pulse to +10 mV to minimize the contribution of 
fast (T-type) current while maximizing the long lasting (L-type) 
component of the current. Notably, N-, P/Q-, and R-type currents are 
still present during this period, as demonstrated in figure 3C, where 
current still remains after the L-type calcium channel antagonist 
nimodipine (20 μM) was used. Thus, the current remaining in the 
presence of nimodipine should primarily be comprised of N-, P/Q-, and 
R-types of calcium current. If CK59 only inhibited L-type channels, 
then the addition of CK59 in the presence of nimodipine should not 
further inhibit the total calcium current because the channels would 
already be blocked. Figure 3C illustrates the calcium current elicited in 
the presence and absence of CK59 (50 μM) in a cell pretreated with 
nimodipine (20μM). The current was reduced with CK59 in a reversible 
manner similarly to the non-nimodipine treated cells. CK59 caused a 
significant decrease in calcium current with an average reduction of 
27.54 ± 4.66% (N = 7, Fig. 3E). The reduction in voltage gated 
calcium current elicited in the presence of the L-type calcium channel 
antagonist implicates that CK59 may inhibit N-, P/Q-, and/or R-type 
current(s). 
Ratiometric calcium imaging experiments were done to confirm 
that CK59 can reduce calcium entry in the presence of an L-type 
calcium channel antagonist. Nimodipine (20 μM) was present in the 
bath for the entire time course of the experiment to block L-type 
calcium channels, and high KCl solution alone or high KCl solution with 
CK59 (50 μM) were applied acutely (Fig. 4). Application of CK59 under 
these conditions reduced high KCl induced calcium entry to 43.73 ± 
1.38% (N = 185) of the average calcium entry elicited by high KCl 
application alone. Given that both calcium current and entry decreased 
in the presence of the L-type calcium channel blocker nimodipine, it 
was hypothesized that CK59 exerts its effects by inhibiting another 
calcium channel type than L-type calcium channels, suggesting a 
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different nonspecific effect from that of CaMKII inhibitor KN93 (Gao et 
al., 2006). However, the effect of CK59 on L-type calcium channels 
may have been masked because nimodipine would already be blocking 
L-type channels in these experiments. Therefore, experiments were 
performed to address the effect of CK59 more specifically on L-type 
channels. 
 
Fig. 4 aMKII inhibitor CK59 attenuates the amount of high KCl induced increase in 
intracellular calcium in the presence of the L-type channel blocker, nimodipine when 
measured with Fura-2 ratiometric imaging. Nimodipine (20 μM) was perfused during 
the entire measurement period. The 340/380 ratio was measured in response to high 
KCl solution before and during CK59 (50 μM) application and representative cells are 
shown (N = 7). Each line represents an individual cell. 
To clarify if L-type calcium channels could also be blocked by 
CK59, ω-conotoxin MVIIC (2 μM) was added to the bath during 
electrophysiological studies to block N- and P/Q-type calcium channels. 
The current in figure 3D is reduced due to the presence of MVIIC. On 
average, cells treated with MVIIC displayed 74.25% less calcium 
current than control cells (data not shown). Comparing the raw current 
in 3C with the L-type channel blocker nimodipine with the raw current 
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in 3D with ω-conotoxin MVIIC suggests that while L-type current is 
certainly present in these neurons, currents sensitive to ω-conotoxin 
MVIIC (N- and P/Q-type) make up the bulk of the high voltage 
activated whole-cell current in neonatal neurons of the superior 
hippocampus when a 300 ms depolarizing pulse is applied. Addition of 
CK59 (50 μM) reduced the current even further, so that very little 
current remained when MVIIC and CK59 were simultaneously applied 
(Fig. 3D). Calcium currents in these studies were decreased an 
average of 67.47 ± 10.38% (N = 5; Fig. 3E), which was a significantly 
larger decrease by CK59 than that seen when ω-conotoxin MVIIC was 
not present (unpaired t-test, p < 0.001, Fig. 3E). Furthermore, total 
calcium current measured in 4 of 5 cells was nearly completely 
abolished with measurements below 10 pA. These data suggest that 
CaMKII nonspecifically inhibits N-, P/Q-, L-, or R-type current, or some 
combination of these currents collectively. 
Discussion 
Data presented here clearly show the off target action of novel 
CaMKII inhibitor CK59 on voltage gated calcium channels. Both 
electrically stimulated currents in whole cell recording and high KCl-
induced calcium influx were significantly reduced by CK59 in a dose-
dependent manner. However, determining the exact channel(s) 
targeted by CK59 is more difficult. Studies done in the presence of ω-
conotoxin MVIIC strongly argue for L-type channel inhibition due to the 
drastic reduction in expected current as well as the nearly complete 
extinction of L-type current in the majority of cells tested when CK59 
was applied. However, in the presence of nimodipine, both calcium 
current and calcium entry decrease upon application of CK59. This 
may seem to suggest that L-type channels are not affected; however 
when nimodipine is present, L-type current is already being blocked. 
Therefore, any effect of CK59 on L-type channels would be masked. 
The decrease in calcium levels in the presence of nimodipine after 
CK59 application does suggest inhibition of additional channels besides 
only the L-type channel. One possibility is that R-type calcium 
channels are inhibited by CK59. In a report by Castelli and Magistretti 
(Castelli and Magistretti, 2006), R-type current in the entorhinal cortex 
made up only 11–13% of total calcium current. The small amount of 
current seen in the cells treated with ω-conotoxin MVIIC also suggests 
a large component of calcium influx is through N- and P/Q-type 
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channels. Even if complete blockade of R-type current was assumed, 
this would likely not make up for the amount of inhibition seen in 
nimodipine-treated cells. There was 27.54% reduction in whole cell 
calcium current and 56.27% reduction in high KCl mediated increase in 
intracellular calcium when nimodipine was present, suggesting that 
even if R-type channels are affected along with L-type calcium 
channels, there must be another channel that is inhibited by CK59. A 
second possibility is that L-type channels were not completely blocked. 
This seems unlikely due to the high concentration of nimodipine used 
in these studies (IC50 = 139 nM for CaV 1.2 and 3 μM for CaV 1.3; 
Catterall et al., 2005). It is more likely that at least one of the 
channels blocked by ω-conotoxin MVIIC is susceptible to inhibition by 
CK59. In either case, it seems that CK59 inhibits L-type channels as 
well as others. While the identity of the other channels CK59 may 
inhibit in addition to L-type channels is not completely clear, it is 
evident CK59 has off target effects that inhibit the entry of calcium 
into neurons. 
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